VEA
IMNM icon

Virtus ETF Advisers’s Immunome IMNM Stock Holding History

Virtus ETF Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,440
Closed -$57.8K – 597
2024
Q4 		$57.8K Sell
5,440
-303
-5% -$3.66K 0.02% 453
2024
Q3 		$84K Buy
5,743
+99
+2% +$1.41K 0.04% 406
2024
Q2 		$68.3K Buy
+5,644
New +$88.3K 0.03% 436

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Virtus ETF Advisers's IMNM Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Immunome (IMNM) in Q1 2025, closing a stake of 5,440 shares — an estimated $57.8K sold.

Virtus ETF Advisers first reported a position in IMNM in Q2 2024 and held it in 3 quarters. The position peaked at $84K in Q3 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,440 Immunome shares in Q1 2025, an estimated $57.8K.
  • Virtus ETF Advisers first reported a position in Immunome in Q2 2024 and held it in 3 quarters.
  • Virtus ETF Advisers's Immunome position peaked at $84K in Q3 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.